Quantcast
Home > Quotes > OHRP
OHRP

Ohr Pharmaceutical, Inc. Common Stock (OHRP) Quote & Summary Data

$0.1325
*  
0.0041
3%
Get OHRP Alerts
*Delayed - data as of Dec. 14, 2018  -  Find a broker to begin trading OHRP now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
Today's High / Low
$ 0.15 / $ 0.13
Share Volume
302,745
50 Day Avg. Daily Volume
1,099,677
Previous Close
$ 0.1366
52 Week High / Low
$ 2.18 / $ 0.1211
Market Cap
7,481,802
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.69

Intraday Chart

Shares Traded

Share Volume:
302,745
50 Day Avg. Daily Volume:
1,099,677

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
Earnings Per Share (EPS):
$ -0.20

Trading Range

The current last sale of $0.1325 is 9.41% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.15 $ 2.18
 Low: $ 0.13 $ 0.1211

Company Description (as filed with the SEC)

We are a clinical stage pharmaceutical company developing novel therapies for ophthalmic diseases. Our lead clinical asset, topical Squalamine (also known as squalamine lactate ophthalmic solution, 0.2%, or OHR-102), is a novel therapeutic product which could provide a non-invasive therapy to improve vision outcomes beyond that achieved with current standard of care. We are evaluating Squalamine in combination with Lucentis┬« injections for the treatment of wet-AMD. This is based on the data from a Phase 2 clinical trial in wet-AMD where a positive and clinically meaningful vision benefit was seen with Squalamine combination therapy in classic containing choroidal neovascularization (classic CNV) as well as those subjects with occult neovascularization (occult CNV) less than 10mm2. We also have a sustained release platform technology which we acquired in May 2014.  ... More ...  

Nasdaq Official Price

Open Price:
$ 0.1434
Open Date:
Dec. 14, 2018
Close Price:
$ 0.1347
Close Date:
Dec. 14, 2018

Research Brokers before you trade

Want to trade FX?

Analyst Info